Orchard Therapeutics, acquired by Kyowa Kirin, announced multiple presentations at the ASGCT 2024, showcasing HSC gene therapy for rare diseases. Data includes positive results for atidarsagene autotemcel, OTL-203 for MPS-IH, and OTL-104 for Crohn's disease. The presentations demonstrate the transformative impact of Orchard's approach and the potential of its pipeline.
Dr. Bobby Gaspar, co-founder and CEO of Orchard Therapeutics, has been named to the 2024 TIME100 Health list for his contributions to gene therapy. Orchard Therapeutics, now owned by Kyowa Kirin, aims to advance gene therapies globally. Dr. Gaspar's recognition highlights his significant impact on transforming treatment for genetic diseases, with key achievements in HSC gene therapy and regulatory approvals in Europe and the U.S.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.